-
公开(公告)号:WO2013010218A1
公开(公告)日:2013-01-24
申请号:PCT/AU2012/000858
申请日:2012-07-16
申请人: FREIE UNIVERSITÄT BERLIN , NEWCASTLE INNOVATION LIMITED , CHILDREN'S MEDICAL RESEARCH INSTITUTE , VOLKER, Haucke , ROBINSON, Phillip , MCCLUSKEY, Adam
IPC分类号: A61K31/00 , A61P31/00 , A61P25/00 , C40B30/02 , C40B50/02 , G06F19/18 , G01N33/15 , C07C13/547 , C07C13/573 , C07C13/66 , C07D221/14 , C07D221/16 , C07D277/20 , C07D277/36 , C07D277/38 , C07D277/34
CPC分类号: A61K31/00 , C07D221/14 , C07D277/34 , C07D277/36 , C07D277/40 , C07D277/42 , C07D277/52 , C07D417/06 , C07D471/06
摘要: Inhibitors are provided for inhibiting the activity of clathrin. In particular, binding site(s) on the clathrin terminal doman (TD) for binding inhibitors have been identified. The binding sites are defined by amino acid(s) in the group Ile 52, Ile 62, Ile 80, Phe 91, and Ile 93 of the clathrin TD (SEQ ID No. 1). In at least some forms, the binding site may be further defined by amino acid(s) in the group Ile 66, Arg 64, Leu 82 andf Lys 96 of SEQ ID No. 1, or by Val 50 of SEQ ID No.1. There are also provided methods for prophylaxis or treatment of disease and conditions responsive to the inhibition of clathrin.
摘要翻译: 提供抑制剂用于抑制网格蛋白的活性。 特别地,已经鉴定了用于结合抑制剂的网格蛋白末端doman(TD)上的结合位点。 结合位点由网格蛋白TD(SEQ ID No.1)的Ile 52,Ile 62,Ile 80,Phe 91和Ile 93中的氨基酸定义。 在至少一些形式中,结合位点可以进一步由SEQ ID No.1的Ile 66,Arg 64,Leu 82和Lys 96的氨基酸或SEQ ID No.1的Val 50进一步定义 。 还提供了用于预防或治疗对抑制网格蛋白有反应的疾病和病症的方法。